Barinthus Biotherapeutics (BRNS) announced the promotion of Geoffrey Lynn to chief scientific officer, or CSO, effective as of December 1. Lynn succeeds Nadege Pelletier, who decided to pursue alternative opportunities closer to home after having served as Barinthus Bio’s CSO since early 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRNS:
- Barinthus Biotherapeutics Reports Promising IM-PROVE II Trial Results
- Barinthus announces results from ongoing Phase 2b HBV003 trial
- Arbutus and Barinthus announce new data from IM-PROVE II trial
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Barinthus Biotherapeutics reports Q3 EPS (21c), consensus (44c)